作　　者： (王翠）; (颜昕）; (赵博军）;

机构地区： 山东大学附属省立医院眼科中心,山东济南250021

出　　处： 《山东大学耳鼻喉眼学报》 2017年第4期94-97,共4页

摘　　要： 目的观察雷珠单抗联合光动力疗法治疗湿性年龄相关性黄斑变性(wAMD)的长期有效性及安全性。方法回顾分析wAMD患者11例(11眼),均在初始接受了玻璃体腔注射雷珠单抗0.5 mg后7 d内联合标准剂量的光动力疗法(PDT),并根据患者复诊情况行玻璃体腔注射雷珠单抗(IVR)再治疗或者观察。统计患者最佳矫正视力(BCVA)、中心视网膜厚度(CRT)、眼压(IOP)及IVR再治疗次数。结果治疗后第2、3、6个月患者BCVA较治疗前提高(P<0.05);治疗后第18个月患者BCVA较治疗前平均提高了(7.31±15.00)个字母,CRT较治疗前下降(P<0.05);IOP治疗前后无统计学差异;前18个月患者IVR再治疗平均次数为1.55次(0~8次)。结论 IVR联合PDT可降低wAMD临床干预次数并延长疗效。 Objective To investigate the potential long-term benefit of combination of intravitreal ranibizumab with photodynamic therapy for the treatment for wet age-related macular degeneration （wAMD）. Methods A retrospective review was conducted on 11 eyes of 11 patients that received intravitreal ranibizumab （IVR） 0.5 mg combined with standard photodynamic therapy （PDT） within 7 days, and thereafter retreatment as required with intravitreal ranibizum- ab monotherapy for at least 18 months. Collected data included： best-corrected visual acuity （BCVA）, central retinal thickness（ CRT）, intraocular pressure （IOP） and number of retreatment. Results The mean BCVA was apparently improved from baseline at the 2nd , 3rd and 6th month of follow-up compared to baseline（P 〈 0.05, showing improve- ment of 7.31 _＋ 15.00 letters from baseline at eighteen months of follow-up. ） Meanwhile, CRT decreased significantly compared with pre-treatment （ P 〈 0.05 ）. During the treatment, IOP kept steady with no statistical difference between pre- and post-treatment. The study eyes received an average of 1.55 times（ range： 0 to 8） of intravitreal anti-VEGF rea- gent injection during the total 18 months period after initial combination therapy. Conclusion Combination therapy could reduce times of intravitreal anit-VEGF reagent injection and maintaine long-lasting effect on wAMD.

关 键 词： 湿性年龄相关性黄斑变性 血管内皮生长因子 光动力疗法 联合疗法